Teva’s generic EpiPen Jr. helps alleviate allergy drug shortage.
Soon after FDA approved generic versions of epinephrine injection USP (EpiPen, Mylan and Pfizer), a pharma maker is releasing a generic EpiPen for children.
Teva Pharmaceutical Industries said the FDA-approved version of EpiPen Jr. 0.15 mg is now available in most retail pharmacies. Teva’s generic version costs $300 per 2-pack.
A year ago, FDA cleared the first generic version of epinephrine, granting Teva authority to make generic versions in 0.3 mg and 0.15 mg strengths.
“This approval means patients living with severe allergies who require constant access to life-saving epinephrine should have a lower-cost option, as well as another approved product to help protect against potential drug shortages.” said former FDA Commissioner Scott Gottlieb, MD, in a statement from FDA, at the time.
There is still a shortage of EpiPens in the U.S., Europe, and Canada. In fact, Pfizer and Mylan worked with FDA in June to extend the expiration dates by four months of all lots of EpiPen Auto-Injectors and its authorized generic version currently on the market in the US.
“Patients should have confidence in using the products as Pfizer works to stabilize supply,” Pfizer and Mylan said in a joint press release.
Meanwhile, Teva will continue working to ensure availability of both generic EpiPen strengths in the US and plan to accelerate production to meet the urgent need for this medicine,” said Brendan O’Grady, EVP and head of North America Commercial for Teva, in a statement.
Read more: FDA approves EpiPen rival